ABSTRACT
InTRoduCTIon
Pituitary tumors constitute 10% of all intracranial tumors and they are associated with local mass effects and marked morbidity due to hormonal secretion (1) . Many subjects regarding molecular pathogenesis of hypophysis adenomas have not been clarified yet. Studies performed recently show that the pathogenesis of pituitary tumor is rather heterogeneous (2) . Recent developments in pituitary tumor genetics made pituitary gland an ideal target for development of new molecular therapies.
Altas M. et al: ACE Genome Insertion/Deletion
We can classify the factors responsible for development of pituitary tumors in four groups: Oncogenes, Tumor suppressor genes, Transcription factors, Autocrine paracrine stimulation (3) . All the components of RAS (renin angiotensin system) are located in the pituitary gland (4, 5) . Many studies have shown that RAS contributes to regulation of hormonal secretion in both the hypothalamus and pituitary gland (6, 7, 8) and also causes activation of protooncogenes through MAP kinase pathway. In animal models, it was shown that RAS components accelerated neovascularization by accelerating the smooth muscle cell proliferation. This is gradually increasing interest in the role of RAS in management of angiogenesis in neoplastic developments (9, 10, 11) . Angiotensin-converting enzyme (ACE) is among zinc metallopeptidase enzyme family and responsible for conversion of Angiotensin 1 to Angiotensin 2. ACE gene is encoded by a 21 Kb gene that consists of 26 exons and is located on the long arm of 17 th chromosome. A polymorphism of the ACE genome involves the insertion (I) or deletion (D) of a 287 base pairs indicated in intron 16. It is known that efficacy of ACE is maximal in homozygote individuals (D/D) and minimal in individuals' homozygote for insertion type polymorphism (I/I). Therefore, individuals with higher ACE level, namely who are homozygote for D allele, are exposed to risks associated with angiotensin 2 much more (12) (13) (14) (15) (16) (17) (18) (19) .
All the components of RAS are located in the pituitary gland and A2 is produced locally. As it is known, hypophyseal adenomas are less vascular than normal hypophysis, and therefore angiogenesis in hypophyseal adenomas is an important model for tumor biology. The aim of the present study was to determine the genotype distribution and allele frequency in ACE genome polymorphism of the patients with pituitary tumors.
MATERIAL and METHodS

Patients
Twenty-one patients who underwent surgical excision of a hypophyseal adenoma were included in the study and the extent of invasion of each hypophyseal adenoma was assessed radiologically and immunohistochemically. Five venous blood samples were taken from each patient and DNA isolation was performed in both the peripheral blood samples and pathologic specimens. For the control group, 5 venous blood samples were taken from 20 healthy volunteers of similar age and DNA isolation was performed from the peripheral blood samples only. Volume was calculated by measuring the three-dimensional lengths of tumor masses on MRI. Cases were classified according to the Hardy-Wezina classification (Table I) .
Preparation of Genomic Deoxyribonucleic Acid
Five milliliters of venous blood sample were collected in tubes containing either acid citrate-dextrose or ethylene diamine tetra acetic acid and were shipped at ambient temperature by overnight courier to the laboratory. The deoxyribonucleic acid (DNA) was prepared from whole-blood lyses of nuclei, which was accomplished by using sodium dodecyl sulfate and proteinase K, followed by phenol-chloroform extraction and ethanol precipitation. The DNA was resuspended in water containing 10 mmol/L Tris (pH 8) and 0.1 mmol/L ethylene diamine tetra acetic acid. Samples were divided into aliquots and diluted to 200 g/ml, after which they were frozen at -80°C.
Genotyping Analysis
DNA isolation was done by taking peripheral venous blood sample from all family members and polymerase chain reactions (PCR) were used to detect insertion: deletion (I/D) polymorphisms of the ACE genome. Genomic DNA, dNTPs and TaqDNA polymerase were used for PCR mixture and primers of HACE3s and HACE3as were used for ACE. The PCR steps were as the following: initial denaturation step at 94°C for 4 minutes, followed by 36 cycles of denaturation at 94°C for 50 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 60 seconds and a final extension at 72°C for 5 minutes. Amplicons obtained were D and I alleles which resulted in 319-bp and 597-bp, respectively. For the verification of these results, another PCR study for the amplification of the D allele was performed. Each sample found to have the D/D genotype was subjected to a second round of PCR amplification with an insertion of specific primer HACE5 forward (5'-TGGGACCACAGCGCCCGCCACTAC-3') and HACE5 reverse (5'-TCGCCAGCCCTCCCATGCCCATAA-3') under the same PCR steps except for an annealing temperature of 60°C. Only the I allele yielded a 335-bp amplicon in the PCR study. PCR products were separated on 2% agarose gel with ethidium bromide staining, visualized by ultraviolet transillumination and stored in digital form (Figure 1 ). Possible mistyping of the ACE I/D genotype as D/D was controlled by the inclusion of dimethyl sulfoxide in the PCR reaction.
Statistical Analysis
All statistical analyses were performed by using 2007 & PASS NCSS Statistical Software 2008 (Utah, USA). The Chi-square test was used to evaluate the data of the study. Statistical significance was defined to be a p value of < 0.05.
RESuLT
The ages of the cases varied between 9 and 69 years and the mean age was 33.31±14.86 years. Fifty-eight of the cases (70.7%) were female and 24 of them (29.3%) male. 4.8% of the cases were Grade I, 28.6% Grade II, 47.6% Grade III and 19% Grade IV. In immunohistochemical findings, GH was determined at a rate of 33,3%; prolactin 52,4%, TSH 4,8%, ACTH 19,0%; LH 4,8% and FSH 4,8% as pathological (Table  II) . No statistically significant differences were seen between ACE genotype distributions in pituitary adenoma and control groups (p>0,05). D/D genotype is high in cases with pituitary adenomas and I/D genotype is high in control cases (Table  III) . Situation of being pathological of GH, prolactin, TSH, ACTH and LH/FSH findings among immunohistochemical parameters does not show statistically significant difference according to ACE genotype measurements and Allele frequency (p>0.05) (Table IV) . There is no statistically Little is known about the genetic events in hypophyseal tumor pathogenesis. Until today, it has been shown that only increased expression of human hypophysis tumor transforming gene (PTTG) was associated with angiogenesis (3). It is known that ACE efficacy is maximum in individuals' homozygote for deletion type polymorphism (D/D) and minimum in individuals' homozygote for insertion type polymorphism (I/I). Therefore, individuals with higher ACE level namely homozygote for D allele are exposed to risks associated with angiotensin 2 much more (7) . All the components of RAS are located in the pituitary gland and A2 is produced locally. Deschepper et al. showed that A2 was synthesized mostly in gonadotropes. In studies performed by the end of 1990s, it has been reported that anterior pituitary of the rat produced usually AT1B isoform of AT1 receptor and AT1B receptors were located usually in lactotropes and to some extent in corticotrope and thyrotropes (4, 5, 9, 18, 19) .
significant difference between volume and grade distribution of the cases according to ACE genotype and Allele frequency (p>0.05) ( Table V) . In conclusion, presence of a higher rate of ACE genome deletion in patients with pituitary adenomas and especially grade 3-4 adenomas suggests that ACE genome polymorphism may be a risk factor for the development of pituitary adenomas.
Many studies showed that A2 contributed to physiological regulation of prolactin secretion from both hypothalamus and pituitary gland (6, 8) . One of the possible functions of endogenous A2 system in hypothalamus is to limit the prolactin secretion against environmental or endogenous stimuli. But A2 conducts this function by exhibiting opposite effects in hypothalamus and pituitary gland. A2 increases prolactin secretion in the pituitary gland and mediates the paracrine effect of GnRH on prolactin secretion (20, 21) .
In the study performed by Pawlikowski, it was reported that A2 produced locally affected the reproductive functions of the anterior hypophysis and other endocrine organs and A2 regulated the prolactin, ACTH and LH secretion and expression of AT2 receptors were associated with tumoral neoangiogenesis and it was shown that both AT1 and AT2 receptors played a role in the control of cell proliferation also in induction of apoptosis.
In animal models, it was demonstrated that A2 induced neovascularization by accelerating smooth muscle cell proliferation (12) . This situation gradually increases the interest toward the role of A2 in regulation of angiogenesis in neoplastic developments. In addition to this, A2 can behave as mitotic factor by inducing or regulating gene expression in cell cycle progression. Effective blockade of A2 receptor decreases the tumor progression developing due to TGF-B1 (transforming growth factor B1) in vivo (22) . Increase of ACE increases G protein synthesis by using MAP (mitogen activated protein) kinase pathway together with growth factor, β-fibroblast growth factor, fibronectin, platelet derived growth factor (β-FGF), transforming growth factor (TGF-β) and vascular endothelial growth factor (VEGF) (20, 23, 24, 25, 26, 27) . In the light of this knowledge, we investigated the relation 
